Ocular Therapeutix (NASDAQ:OCUL) Stock Rating Reaffirmed by JMP Securities

JMP Securities restated their market outperform rating on shares of Ocular Therapeutix (NASDAQ:OCUL – Free Report) in a report released on Tuesday morning, Benzinga reports. The brokerage currently has a $24.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a buy […]

Related Keywords

United States ,China ,Vermont ,America ,Piper Sandler ,Rabia Gurses Ozden ,Steward Partners Investment Advisory ,Ocular Therapeutix Company Profile ,Ocular Therapeutix Inc ,China Universal Asset Management Co ,Securities Exchange Commission ,Tower Research Capital ,Ocular Therapeutix ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,Summer Road Llc ,Universal Asset Management ,Partners Investment Advisory ,Research Capital ,Ocular Therapeutix Daily ,Nasdaq Ocul ,Hocul ,Medical ,Reiterated Rating ,Jmp Securities ,